My prediction of the first Catalyst is acceptance of mTNBC
My prediction of the first Catalyst is acceptance of mTNBC BTD followed by good Nash results that will also be filed as a BTD and accepted in the first quarter. The Brazil Covid trials will also fill and seek EUA with hopefully great results that are heard world wide.
When we voted for the 200 million authorized shares for this year the hope was that the first quarter would see a rise in stock price as these indications showed promise and great results which would start our accent in stock price.
Nader said that we would see more value in the 200 million shares as the price went up and that it would give us bargaining strength with a possible partner. Nader also said something very important if you listened closely. If we don’t receive a proper or good offer to partner for whatever is our first partnership that we don’t have to accept a insufficient offer because of our strength in shares.
What this meant to me is if we do not receive a good offer for just one and not all of our indications because we do not want a partner for all our indications. This much is clear. The difficulty will be keeping a partner to just one indication and a good offer to partner for that one indication. We have the 200 million shares that would of had a value increase by this time with a BTD accepted for mTNBC, another filing for BTD for brain metastasis, Nash results with a following filing of BTD, a possible Critical Covid results that could bring a EUA internationally and filing of our BLA for Duel HIV all in the first quarter. The opportunities this provides for us all should not be overlooked.
The values increase in the 200 million shares will be much more and the strength it gives us could be 5-20 times its current value or even more. With potential like this and say something in the middle like $10/share price with all these catalysts happening all close together. The value could be as much as 2 billion dollars. This is what Nader was trying to deliver without putting a number on the value like I just did. If we have this kind of value it allows us the opportunity to not take any measly low ball offer to partner and gives us much more control of our destiny. We will not accept a low ball offer with a billion or more dollars in stock value. We will be able to afford to go our own way and finance our company into a massive growth in growing into our own big pharmaceutical company. This is what Nader and Scott have said on a few occasions. We should have the ability to go either direction. Partner or not to partner. This is our strength for having authorized the 200 million shares.
I hoped that the strength and the timeline would all happen in the first quarter of 2022. This all still looks possible to me. My choice has always to see our stock value increase exponentially to $5-20 dollars a share and build ourselves into a future mammoth pharmaceutical company. The real deal is to grow by ourselves and the highest return on our investment is to grow alone. With a billion or two billion dollars or what could be much more… who needs a partner to steal half of our profits?
In any case going forward. Authorizing the 200 million stock shares allowed us the power to pick our own path. Either… a one indication partnership or go it alone. This was a wise move by Nader and Scott to put us in this position and shows they look to our future for shareholders value. I really look forward to the next few months as it will define who we are and who we will become. Let’s hope the shortsightedness of a buy-out does not raise its ugly head. Because that is the worst case scenario a CYDY shareholder could see. I would never vote for a buy-out and accept pennies on the dollar for our potential to see some other big Pharma steal our potential and our chance of becoming a bigger pharmaceutical company. Hell… maybe in a few years from now we buy out Merck or Gilead? With 90+ indications and a huge amount of block Buster potential indications… this could be entirely possible. Don’t underestimate our future potential… the stars are aligning in my opinion. How we as shareholders end up voting when the time comes… will set our direction and our future. My vision is we go it alone and become the biggest pharmaceutical company… wouldn’t that be the ultimate? This is my 2 cents of an opinion. Take it for what it is worth. It won’t buy you a cup of coffee but it makes for nice dreams… my dreams sometime come true in my world. Let’s hope this is one of them that becomes true!
14
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
When the suits start flying, folks, you know there's a mess brewing somewhere in the market. Here we are, talking about AEVEX Corp, ticker NYSE:AVEX, and they’re facing some serious heat. There's some scuttlebutt about a class action lawsuit that’s got investors clutching onto their wallets tighter than ever. If you’ve been scouring over the papers, this lawsuit is...
Continue Reading
Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...
Continue Reading
Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...
Continue Reading
IFA Unveils a Game-Changer for Senior Living Imagine having a helper at home that not only looks out for your safety but also keeps you company. That's exactly what Tuya Smart's new AI creation, Doova, is set to do. Unveiled at the IFA 2026, Doova isn't just another gadget—it’s a big leap for folks choosing to live out their golden years independently. Navigating...
Continue Reading
Adapt or Get Left Behind: The Texas Insurance Scene In a world where costs are ballooning and the pressure on the wallet grows heavier, here comes Bamboo Insurance swinging into Texas like a hopeful knight. This plucky insurer is rolling out the Texas Essential Homeowner Program, a highly adaptable, admitted policy that promises to put some power back into the hands of...
Continue Reading
Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...
Continue Reading
Exploring New York Without Breaking the Bank Tough times call for creative solutions, and AARP New York is on the ball. With travel costs soaring and many older New Yorkers scrimping to make ends meet, the 'Staycation' campaign steps in with an offer too good to pass up: uncovering the gems of New York right under our noses without shelling out hefty sums. The plan? Turn...
Continue Reading
Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...
Continue Reading
FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...
Continue Reading
Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...
Continue Reading
Top 5 Most Recently Viewed Articles
The Preservation of Gulangyu: A Cultural Treasure In the enchanting island of Gulangyu, known for its rich musical history, Ian Wakeley, a talented pipe organ engineer, is diligently working on the restoration of a magnificent theater organ that contributes to the island's impressive collection of over seventy organs. This effort marks a significant step in preserving not...
Continue Reading
Advance Magazine Seeks Credit Facility Backed by Reddit Shares Advance Magazine, a prominent shareholder of Reddit Inc (NYSE: RDDT), is making strategic financial moves by planning to establish a credit facility utilizing its stake in the social media platform. As reported by Bloomberg, this significant initiative aims to leverage the company’s investment to enhance its...
Continue Reading
April 2025 Rankings Overview by Pixalate In a recent development, Pixalate, a prominent global player in ad fraud protection and analytics, launched the Publisher Trust Index (PTI) for various regions including the Netherlands. This innovative index examines the performance of websites and mobile apps on notable platforms such as the Apple App Store and Google Play Store,...
Continue Reading
UBS Group AG: A Five-Year Journey Owning stock in UBS Group AG (NYSE: UBS) has proven to be a rewarding venture for investors over the last five years. This illustrious company has demonstrated an impressive ability to outperform the broader market, showing a notable annualized return that outstrips many competitors. With a market capitalization standing firmly at $128.03...
Continue Reading
Charlie Munger's Approach to Financial Success The late billionaire Charlie Munger shared invaluable insights into financial longevity that many find inspiring. He focused on steering clear of the traditional paths that lead to failure, highlighting a cautious approach to life and business. The Core Philosophy Munger's strategy was both simple and effective. He emphasized...
Continue Reading